Obesity & PD-1: History Doesn’t Repeat But It Rhymes
Insights - The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns to that of checkpoint inhibitors … Continue Reading
Read NowInsights
IL-18 Names Picking Up Interest in Cancer
Insights - One of the names we wrote about back in mid-December as a trade due to its ample cash position and negative enterprise value was Mural … Continue Reading
Premium: Read Now
GLP & MASH Names Heating Up With More Data Announcements
Insights - In a prior note, we covered the impact that GLP-1 drug class would have on related markets. On this note, we’ll focus on NASH (now … Continue Reading
Read Now
Transcript of KOL Call: Urologist Talks Bladder Cancer and Lasting Side Effects
Insights - Participants PropThink Dr. Michael Chancellor, KOL Jonathan Kaufman, Lipella CEO PropThink Good afternoon everyone, welcome to PropThink’s Digital Conference. My name is Deniel Mero, Editor … Continue Reading
Read Now
Modular Medical Submits 510(k) for Insulin Patch Pump
Insights - Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately six months to approve devices … Continue Reading
Premium: Read Now
2024 Trends to Watch as Biotech Makes Comeback
Insights - Biotech has roared back and seen a strong start to the new year. Since November, in less than 3 months, the XBI is up 32%. … Continue Reading
Read Now
Big Pharma’s M&A Strategy Is Likely to Stay the Same in 2024
Insights - Bristol Myers Squibb announced the acquisition of Karuna (KRTX) for $14B to add a first-in-class schizophrenia drug and neuroscience pipeline. You can read more about … Continue Reading
Read Now